ANN ARBOR, Mich., May 19, 2017 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has delivered the first samples of Dragon Silk to the US Army for independent testing. The Company provided several samples of individual silk filaments as well as finished Dragon Silk thread for evaluation.
"We are pleased to report that we have delivered the first samples of Dragon Silk to our US Army sponsor for independent performance confirmation,” said the Company’s COO Jon Rice. “These samples mark the starting point for what we hope will be a long lasting and profound impact on protective equipment for those dedicated to protecting us. The speed that our Indiana facility was able to ramp up to meet this request helps to confirm, that we have the ability to promptly deliver a top quality, cost effective, fiber to the Army and future commercial customers.”
The Company is producing Dragon Silk at its Indiana factory and expects to make final delivery of the shoot packs for ballistic testing later this year.
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.
For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC (720) 288-8495 [email protected]


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



